Medicenna Therapeutics (TSE:MDNA) Shares Down 2.5% – What’s Next?

Medicenna Therapeutics Corp. (TSE:MDNA)’s stock price traded down 2.5% during trading on Wednesday. The company traded as low as C$0.38 and last traded at C$0.39. Approximately 82,525 shares changed hands during trading, a decline of 5% from the average session volume of 87,218 shares. The stock had previously closed at C$0.40.

Medicenna Therapeutics Trading Down 2.5%

The firm has a market capitalization of C$35.54 million, a P/E ratio of -1.75 and a beta of 3.00. The company has a debt-to-equity ratio of 6.22, a quick ratio of 4.65 and a current ratio of 1.25. The firm has a 50 day moving average price of C$0.41 and a two-hundred day moving average price of C$0.48.

Medicenna Therapeutics Company Profile

Medicenna is a clinical-stage immunotherapy company developing engineered cytokine therapies designed to selectively engage the immune system to treat cancer. The Company’s most advanced program, bizaxofusp (formerly MDNA55), is a targeted IL-4 Empowered Superkine that has been evaluated in more than 130 patients across five clinical trials, including a Phase 2b study in recurrent glioblastoma. Bizaxofusp has received Fast Track designation from the FDA and Orphan Drug designation in the United States and Europe.